Dario Bottigliero

Dr. Dario Bottigliero


Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 August 2019 in Journal of Interventional Cardiac Electrophysiology
Verified
Journal Article
Closed access
PDF file
Dario BottiglieroDario Bottigliero
Dario Bottigliero
IMIlenia Monaco
Ilenia Monaco
RSRosa Santacroce
Rosa Santacroce
GCGrazia Casavecchia
Grazia Casavecchia
MCMichele Correale
Michele Correale
NBNatale Daniele Brunetti
Natale Daniele Brunetti

23 October 2025 in The Heart Surgery Forum
Verified
Journal Article
Open access
ICInsaf Chouarfia
Insaf Chouarfia
IMIlenia Monaco
Ilenia Monaco
MSMounia Sedrati
Mounia Sedrati
FBFatima S. Bouhaik
Fatima S. Bouhaik
VTValeria Trivelloni
Valeria Trivelloni
Dario BottiglieroDario Bottigliero
Dario Bottigliero
Cardiac masses pose a significant diagnostic challenge, requiring a structured imaging-based approach. Echocardiography represents the first-line and most essential diagnostic tool, providing a rapid, non-invasive, and cost-effective method for detecting and characterizing intracardiac lesions. While metastatic involvement is the most frequent cause of secondary cardiac masses, the primary tumors are predominantly benign. However, distinguishing between tumors, thrombi, and pseudotumors often necessitates advanced imaging techniques, such as cardiac magnetic resonance imaging (MRI) or computed tomography (CT). Meanwhile, in addition to the diagnostic role, imaging techniques are essential for risk stratification and guiding therapeutic decisions. Thus, a multidisciplinary approach integrating multiple imaging modalities is crucial for optimizing patient management and improving outcomes.

13 March 2025 in The Heart Surgery Forum
Verified
Journal Article
Open access
PDF file
VTValeria Trivelloni
Valeria Trivelloni
SSStefano Salvini
Stefano Salvini
IMIlenia Monaco
Ilenia Monaco
FBFatima Samet Bouhaik
Fatima Samet Bouhaik
ICInsaf Chouarfia
Insaf Chouarfia
Dario BottiglieroDario Bottigliero
Dario Bottigliero
Percutaneous coronary intervention (PCI) has significantly improved the management of ischemic heart disease, particularly with the advent of drug-eluting stents (DES), which have substantially lowered the incidence of stent thrombosis compared to bare-metal stents (BMS). Despite this progress, complications such as stent thrombosis, though less frequent, remain clinically relevant. From a pharmacological perspective, dual antiplatelet therapy (DAPT) plays an essential role in minimizing the risk of stent thrombosis, albeit at the cost of an increased bleeding risk. Over time, the duration of DAPT has been progressively shortened, largely attributable to advancements in DES technology, which offer improved safety and efficacy profiles. This review examines clinical trials, randomized controlled studies, and meta-analyses conducted between 2020 and 2024 to evaluate the effectiveness of short-term DAPT in patients receiving DES, with a particular emphasis on the post-myocardial infarction (MI) setting. Emerging data indicate that shorter DAPT regimens do not elevate the risk of stent thrombosis while markedly reducing bleeding complications, thereby endorsing a more concise treatment approach without compromising safety outcomes. Furthermore, the impact of novel technologies and the increasing adoption of personalized therapeutic strategies are explored, underscoring their importance in optimizing clinical outcomes.

Verified
Journal Article
Open access
PDF file
FBFatima Zahra Samet Bouhaik
Fatima Zahra Samet Bouhaik
IMIlenia Monaco
Ilenia Monaco
MSMounia Sedrati
Mounia Sedrati
ABAlix Bouvet
Alix Bouvet
BGBenedicte Gervais
Benedicte Gervais
Dario BottiglieroDario Bottigliero
Dario Bottigliero
Systolic anterior motion (SAM) of the mitral valve can occur either in association with or in the absence of hypertrophic obstructive cardiomyopathy (HOCM). SAM induces dynamic left ventricular outflow tract obstruction (LVOTO) and, in the majority of cases, is associated with a substantial degree of mitral regurgitation (MR) that significantly impacts patient morbidity and mortality. This narrative review explores the contemporary understanding of the pathophysiology, diagnosis, and management of SAM, focusing particularly on surgical strategies and the novel therapeutic class of cardiac myosin inhibitors. Extended septal myectomy remains the gold-standard treatment for HOCM-related SAM, yielding superior long-term outcomes compared to alcohol septal ablation (ASA). Advanced imaging modalities, including three-dimensional transesophageal echocardiography (3D-TEE), enable precise pre-operative characterization of the mitral valve apparatus. Some patients may benefit from septal reduction strategies while concomitant mitral valve interventions are generally reserved for highly selected cases with intrinsic valve pathology or persistent residual SAM, thereby avoiding unnecessary valvular manipulation and its potential hemodynamic risks. Mavacamten, a selective cardiac myosin inhibitor, represents an important advance in pharmacological management, achieving a mean LVOT gradient reduction of 37.2 mmHg in symptomatic patients. Furthermore, data from the MARVEL registry confirm the real-world clinical efficacy of mavacamten in obstructive hypertrophic cardiomyopathy, with 86% of patients successfully down-staged to NYHA functional class I–II. Although ASA serves as a viable alternative to surgery, it entails a higher risk of conduction abnormalities requiring permanent pacemaker implantation and subsequent re-intervention. Beyond classical hypertrophic SAM, this review addresses the diagnosis and management of post-mitral repair complications and non-hypertrophic variants. Optimal management and risk stratification remain an evolving field requiring a multidisciplinary Heart Team approach, leverage of advanced imaging, and adoption of novel medical therapies. Interventional strategies must be carefully tailored to maximize the efficacy-to-safety profile on an individualized patient basis.

10 November 2026 in Medical Sciences
Verified
Journal Article
Open access
PDF file
Dario BottiglieroDario Bottigliero
Dario Bottigliero
Cardiac Amyloidosis (CA) is often underdiagnosed and diagnosed late because its phenotype overlaps with that of hypertensive cardiovascular disease, hypertrophic cardiomyopathy (HCM), aortic stenosis and heart failure with preserved ejection fraction (HFpEF). Transthoracic echocardiography serves as the primary clinical gateway for screening, yet standard visual interpretation remains limited by operator dependence and variability in recognizing subtle features. Artificial intelligence (AI) is transforming this pathway through two principal paradigms: the automation of image acquisition, view classification, and deformation imaging (e.g., global longitudinal strain), as well as end-to-end deep video learning alongside radiomic texture analysis. Recent multicentre validations demonstrate that video-based deep neural networks can detect CA with high accuracy in external cohorts, while feature-based and radiomic approaches aim to capture subtle, spatial structural patterns that may escape routine visual assessment, offering complementary quantitative metrics. While spatial heatmaps such as Grad-CAM can provide good visual intuition about what parts of the image a model used to make a classification decision, they do not provide any true insight into the underlying pathophysiology. This narrative review assesses the current clinical applications of AI in echocardiography for the screening of cardiac amyloidosis. Automated workflows, deep video architectures, and the use of radiomics are presented, along with several different explainable AI (XAI) frameworks. The review also outlines the challenges to the safe clinical application of AI in echocardiography from a regulatory, ethical, and governance perspective.

Verified
Journal Article
Open access
PDF file
IMIlenia Monaco
Ilenia Monaco
MSMounia Sedrati
Mounia Sedrati
ICInsaf Chouarfia
Insaf Chouarfia
FBFatima Zahra Samet Bouhaik
Fatima Zahra Samet Bouhaik
VTValeria Trivelloni
Valeria Trivelloni
Dario BottiglieroDario Bottigliero
Dario Bottigliero
Background: Amyloidosis is an infiltrative cardiomyopathy caused by amyloid deposition into the myocardium. In recent years, recognition of this treatable cause of heart failure has increased. There are striking sex differences in the diagnosis, clinical course and outcome of the disease. Notably, women have a worse prognosis than men with similar amounts of cardiac involvement. Methods: This review provides an overview of the current state of knowledge regarding the epidemiology, clinical features, diagnosis and treatment of amyloid heart disease. The differences observed between men and women are discussed, and recent advances in the field are highlighted. Results: Compared to men, women are generally older at diagnosis, appear to have less severe cardiac disease at the time of impairment and are more frequently diagnosed late. The less apparent disease manifestations in women may be responsible for the delay in diagnosis. Moreover, women may be underdiagnosed when sex-neutral diagnostic criteria are used. Conclusions: Addressing diagnostic disparities may require the use of sex-specific diagnostic thresholds, as well as a more expansive use of multimodality imaging. Future clinical trials should aim to enroll a greater number of female participants to inform optimal therapeutic approaches and to define the sex-specific disease phenotype for this increasingly treatable disease.